CRISPR Therapeutics has a 12-month low of $30.96 and a 12-month high of $67.88. CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th.

CRISPR Therapeutics (NASDAQ:CRSP) shares snapped six straight sessions of losses on Wednesday, as the stock closed 3% to $34.18. The Switzerland-based biotech company lost about 19% in the ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $32.65, marking a -0.03% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 5.98%.

ZUG, Switzerland and BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) have been assigned a consensus recommendation of “Hold” from the twenty-one ratings firms that are covering the stock ...

CRISPR Therapeutics' stock is down 19% since December, with a slow Casgevy launch and significant R&D investments, yet strong cash reserves provide a safety net. Q4 earnings show no revenue from ...

CRISPR Therapeutics experienced an 12% price decline over the last week, coinciding with significant market disruption driven by escalating tariff tensions, which saw the S&P 500 and Nasdaq drop 10% ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP), a pioneer in gene-based medicine, has announced that Chief Operating Officer Julianne Bruno is set to leave the company on April 11, ...